Kimberly Blackwell - Feb 1, 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Executive Officer, Director
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Stock symbol
ZNTL
Transactions as of
Feb 1, 2024
Transactions value $
-$241,457
Form type
4
Date filed
2/5/2024, 07:11 PM
Previous filing
Nov 13, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +250K +98.12% $0.00 505K Feb 1, 2024 Direct F1
transaction ZNTL Common Stock Tax liability -$241K -20.7K -4.09% $11.69 484K Feb 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +250K $0.00 250K Feb 1, 2024 Common Stock 250K $11.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2 Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person.
F3 The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.